# Imaging and Liquid Biopsy for Glioma Diagnosis and Treatment Monitoring

> **NIH NIH R01** · MASSACHUSETTS GENERAL HOSPITAL · 2022 · $614,253

## Abstract

Malignant gliomas (MG) are the most aggressive malignancy of the central nervous system with the mean
survival time of 15 months. Fast progression and high heterogeneity of MG mandates frequent imaging (MRI)
to measure therapeutic responses. Imaging alone, however, is limited by false positives (“pseudoprogression”)
and lacks molecular specificity. Tissue analyses could augment imaging results, but carries the risk of
comorbidity and sampling errors. The goal of this project is to address such challenges and advance a
minimally invasive, hence serially repeatable clinical assay specific to MG. We will exploit extracellular
vesicles (EVs) as a new class of circulating cancer biomarker. Increasing number of studies evidence EVs'
potential utility: these vesicles, are released from all cells, function as reliable cellular surrogates and reflect
global tumor burden, overcoming limitations of tumor heterogeneity and sampling bias. We now seek to
establish a translational EV assay for MG diagnosis and treatment monitoring, and compare its performance
with gold standard imaging-based diagnostics. First, we will standardize EV assay protocols for clinical
workflow. We will adopt our validated technologies: ExoLution, a clinical grade kit for EV isolation; Shahky, a
high-throughput plasmonic instrument for EV protein analyses; and digital droplet PCR for highly sensitive EV
mRNA detection. Leveraging the developmental and regulatory expertise of Exosome Diagnostics, we will
make these platforms ready for translation into clinical diagnostic laboratories. Second, we will perform a
targeted clinical study, critically assessing EVs' diagnostic and prognostic capacity for GBM. We will collect
circulating EVs from GBM patients undergoing therapies and monitor serial changes of EV protein/mRNA
profiles, particularly to detect the early sign of acquired resistance. We will compare results from EV assays
and accompanying MRI, and build an integrative model for treatment monitoring. We formed a powerful
multidisciplinary team to conduct these projects: Brain Tumor Center at Massachusetts General Hospital
(MGH) which operates a vast biobank program of human clinical samples; Center for Systems Biology at
MGH, a pioneer in developing new technologies for EV analyses; and Exosome Diagnostics, a de-facto
industry leader in EV-based liquid biopsy with extensive experience in assay standardization. Collectively, the
team has a track record of studying EVs' potential as a gliomas biomarker and has established optimal EV
assays for molecular analyses. We will ensure assay reliability and reproducibility to deliver clinically
translatable EV tests. We will also impose stringent quality controls on assay design and sample processing,
accrue well-annotated patient and control samples, and perform statistically powered clinical studies. The
technical and scientific outcomes of this research could have a significant translational impact in gliomas
care by establishing a robust...

## Key facts

- **NIH application ID:** 10359166
- **Project number:** 5R01CA239078-03
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Bob S Carter
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $614,253
- **Award type:** 5
- **Project period:** 2020-03-01 → 2025-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10359166

## Citation

> US National Institutes of Health, RePORTER application 10359166, Imaging and Liquid Biopsy for Glioma Diagnosis and Treatment Monitoring (5R01CA239078-03). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10359166. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*